| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0168-8278(00)80421-3 |
| P698 | PubMed publication ID | 10728800 |
| P2093 | author name string | Poupon R | |
| Poupon RE | |||
| Chazouillères O | |||
| P2860 | cites work | A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis | Q22004274 |
| Mutations in the human Jagged1 gene are responsible for Alagille syndrome | Q24314702 | ||
| Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1 | Q24314766 | ||
| Phosphatidylcholine translocase: a physiological role for the mdr2 gene | Q24319732 | ||
| Spectrum and frequency of jagged1 (JAG1) mutations in Alagille syndrome patients and their families | Q24538971 | ||
| Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7alpha-hydroxylase gene causes severe neonatal liver disease | Q24564340 | ||
| Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis | Q24681704 | ||
| Mutations in JAGGED1 gene are predominantly sporadic in Alagille syndrome | Q28142606 | ||
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis | Q28264570 | ||
| Delta 4-3-oxosteroid 5 beta-reductase deficiency described in identical twins with neonatal hepatitis. A new inborn error in bile acid synthesis | Q28361181 | ||
| Familial giant cell hepatitis associated with synthesis of 3 beta, 7 alpha-dihydroxy-and 3 beta,7 alpha, 12 alpha-trihydroxy-5-cholenoic acids | Q28361624 | ||
| Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production | Q28379482 | ||
| Hepatic ductular hypoplasia associated with characteristic facies, vertebral malformations, retarded physical, mental, and sexual development, and cardiac murmur | Q28646354 | ||
| Genetic basis of progressive familial intrahepatic cholestasis | Q33715915 | ||
| Features of Alagille syndrome in 92 patients: frequency and relation to prognosis | Q33853650 | ||
| Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis | Q34062436 | ||
| Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis | Q34377943 | ||
| Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis | Q34409622 | ||
| Congenital diseases of intrahepatic bile ducts: variations on the theme "ductal plate malformation" | Q35380232 | ||
| Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2 | Q35610980 | ||
| Liver cirrhosis induces renal and liver phospholipase A2 activity in rats | Q37357590 | ||
| A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation | Q37383640 | ||
| Small-duct primary sclerosing cholangitis | Q37755861 | ||
| HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis. | Q38484317 | ||
| Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals | Q39225838 | ||
| Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts? | Q39858738 | ||
| Cholangitis associated with paroxysmal nocturnal hemoglobinuria: another instance of ischemic cholangiopathy? | Q40413015 | ||
| Genetic factors in primary biliary cirrhosis | Q40634963 | ||
| Familial primary biliary cirrhosis | Q40634968 | ||
| Immunogenetics of chronic liver diseases | Q40758117 | ||
| Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
| Biliary atresia: current concepts and research directions. Summary of a symposium | Q41011522 | ||
| A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody | Q41199465 | ||
| Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. | Q42555482 | ||
| Involvement of microtubules in the swelling-induced stimulation of transcellular taurocholate transport in perfused rat liver | Q42797129 | ||
| T lymphocytes from patients with primary biliary cirrhosis produce reduced amounts of lymphotoxin, tumor necrosis factor and interferon-gamma upon mitogen stimulation | Q43656613 | ||
| Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid | Q43893454 | ||
| Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis | Q43948285 | ||
| Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis | Q44772320 | ||
| Elevations in IFN-gamma, IL-5, and IL-10 in patients with the autoimmune disease primary biliary cirrhosis: association with autoantibodies and soluble CD30. | Q45948263 | ||
| In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset | Q46177088 | ||
| Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. | Q50629106 | ||
| Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. | Q51597193 | ||
| A new peak in the ALPS | Q57078484 | ||
| Cirrhosis of the Liver induced in Rabbits by Gastric Instillation of 3-Monohydroxycholanic Acid | Q58954889 | ||
| Enhanced expression of TNFα in patients with primary biliary cirrhosis | Q60647665 | ||
| Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status | Q62395194 | ||
| HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis | Q68037897 | ||
| Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man | Q68583675 | ||
| Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids | Q68693124 | ||
| Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? | Q69896715 | ||
| Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens | Q69917880 | ||
| Tauroursodeoxycholate prevents taurocholate induced cholestasis | Q70316364 | ||
| Molecular aspects of membrane stabilization by ursodeoxycholate [see comment] | Q70457384 | ||
| Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy | Q70670255 | ||
| Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis | Q70912535 | ||
| Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes | Q71035961 | ||
| Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis | Q71057890 | ||
| Sclerosing cholangitis: broad spectrum of radiographic features | Q71353959 | ||
| Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis | Q71603498 | ||
| Familial Giant Cell Hepatitis with Low Bile Acid Concentrations and Increased Urinary Excretion of Specific Bile Alcohols: A New Inborn Error of Bile Acid Synthesis? | Q71835309 | ||
| Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis | Q71949350 | ||
| In situ nucleic acid hybridization of pyruvate dehydrogenase complex-E2 in primary biliary cirrhosis: pyruvate dehydrogenase complex-E2 messenger RNA is expressed in hepatocytes but not in biliary epithelium | Q71949355 | ||
| Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes | Q72164376 | ||
| Antibodies to carbonic anhydrase in patients with immune cholangiopathies | Q72281881 | ||
| Autoimmune cholangitis: a variant of primary biliary cirrhosis. Clinicopathologic and serologic correlations in 200 cases | Q72313586 | ||
| Ursodeoxycholic acid in the treatment of primary biliary cirrhosis | Q72401649 | ||
| Genetic abnormalities of immunoregulation in primary biliary cirrhosis | Q72786950 | ||
| Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis? | Q72800622 | ||
| Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group | Q73090826 | ||
| Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis | Q73107770 | ||
| Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study | Q73167014 | ||
| Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis | Q73319901 | ||
| Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation | Q73491973 | ||
| Peribiliary vascular plexus in primary sclerosing cholangitis and primary biliary cirrhosis | Q73513621 | ||
| Mitogen-activated protein kinases mediate the stimulation of bile acid secretion by tauroursodeoxycholate in rat liver | Q73760652 | ||
| The human biliary epithelial cell plasma membrane antigen in primary biliary cirrhosis: pyruvate dehydrogenase X? | Q73835534 | ||
| Dihydroxy bile acids activate the transcription of cyclooxygenase-2 | Q74088917 | ||
| Analysis of serum cytokine levels in primary biliary cirrhosis patients and healthy adults | Q74386488 | ||
| Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression | Q74645177 | ||
| Recurrence of primary sclerosing cholangitis following liver transplantation | Q74645199 | ||
| Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy | Q77058192 | ||
| Frequency and nature of the variant syndromes of autoimmune liver disease | Q77058224 | ||
| A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis | Q77338415 | ||
| Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis | Q77386845 | ||
| A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group | Q77499263 | ||
| Expression of pyruvate-dehydrogenase complex PDC-E2 on biliary epithelial cells induced by lymph nodes from primary biliary cirrhosis | Q77647596 | ||
| Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis | Q77716502 | ||
| Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group | Q77807948 | ||
| Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial | Q77872001 | ||
| In situ nucleic acid detection of PDC-E2, BCOADC-E2, OGDC-E2, PDC-E1alpha, BCOADC-E1alpha, OGDC-E1, and the E3 binding protein (protein X) in primary biliary cirrhosis | Q77933473 | ||
| Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis | Q77933487 | ||
| P433 | issue | 1 Suppl | |
| P304 | page(s) | 129-140 | |
| P577 | publication date | 2000-01-01 | |
| P1433 | published in | Journal of Hepatology | Q15724402 |
| P1476 | title | Chronic cholestatic diseases | |
| P478 | volume | 32 |
Search more.